| Nov 10 |
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 8 |
Evoke Pharma GAAP EPS of -$0.94, revenue of $2.65M
|
| Nov 7 |
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
|
| Nov 4 |
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
|
| Oct 29 |
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
|
| Oct 28 |
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis
|
| Oct 28 |
Evoke stock rockets 90% on study of Gimoti in GLP-1 users
|
| Oct 28 |
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
|
| Oct 23 |
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
|
| Oct 22 |
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
|
